Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
According to the World Health Organization (WHO), over 422 million people globally live with diabetes, while obesity has nearly tripled since 1975, with more than 1 billion individuals affected, significantly increasing demand for effective GLP-1-based therapeutic interventions worldwide
Three days of intraperitoneal LPS administration increased microglial activation (measured by IBA1 immunoreactivity) dose-dependently in both hippocampus and whole brain at the semi-acute time point
Across GLP-1 and incretin-based therapies, we are seeing outcomes beyond the scale: - fewer major cardiovascular events - kidney protection - improvements in conditions tightly linked to cardiometabolic dysfunction, including sleep apnea biology We should stop treating obesity as a cosmetic problem and start treating it like the systemic disease driver it is, across joints, heart, kidneys, and sleep
Fill half of it with veggies, add a quarter of lean protein, and finish with whole grains or healthy fats
Setting attainable goals can prevent disappointment and encourage persistence, even when progress seems slow
